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Behçet’s disease (BD) is a multi-systemic inflammatory disorder consisting of recurrent 
oral aphthosis, genital ulcers, and chronic relapsing bilateral uveitis; however, many other 
organs may be affected. Several pro-inflammatory cytokines, mainly derived from Th1 
and Th17 lymphocytes, seem to be involved in different pathogenic pathways leading to 
development of the clinical manifestations. On this basis, the primary aim of our study 
was to compare a core set of pro-inflammatory cytokines between patients with BD and 
healthy control (HC). The secondary goal was to evaluate potential correlations between 
these putative circulating biomarkers, the status of disease activity, and the specific 
organ involvement at the time of sample collection. Fifty-four serum samples were 
collected from 46 BD patients (17 males, 29 females, mean age 45.5 ± 11.3 years), 
and 19 HC (10 males, 9 females, mean age 43 ± 8.3 years). Twenty-five serum cyto-
kines (APRIL/TNFS13, BAFF/TNFSF13B, sCD30/TNFRSF8, sCD163, Chitinase3-like1, 
gp130/sIL-6Rb, IFNb, sIL-6Ra, IL-10, IL-11, IL-19, IL-20, IL-26, IL-27 (p28), IL-28A/
IFN-lambda2, IL-29/IFN-lambda1, IL-32, IL-34, IL-35, LIGHT/TNFSF-14, Pentraxin-3, 
sTNF-R1, sTNF-R2, TSLP, and TWEAK/TNFSF-12) were simultaneously quantified 
using a Bio-Rad cytokine bead arrays. Serum concentration of sTNF-R1 (p <  0.01) 
and sTNF-R2 (p < 0.01) resulted higher in both active and inactive BD than HC, while 
Chitinase3-like1 (p < 0.05) and gp130/sIL-6Rb (p < 0.01) serum levels were significantly 
higher in inactive BD, and IL-26 (p < 0.01) in active BD than HC. No differences were 
observed between inactive and active BD group. In addition, we observed that gp130/
sIL-6Rb, sIL-6Ra, IL-35, and TSLP serum levels were significantly enhanced in patients 
with mucocutaneous manifestations plus ocular involvement (MO-BD) compared to 
subgroup with only mucocutaneous involvement (M-BD). Our findings may suggest a 
signature of IL-6, tumor necrosis factor-α as well as of Th17 response in BD patients 
due to increased levels of gp130/sIL-6Rb, sTNF-R1, sTNF-R2, IL-26, respectively. This 
evidence could contribute to improve the knowledge regarding the role of these citokines 
in the induction of specific BD clinical features.
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TaBle 1 | Demographic, laboratory, and clinical characteristics of 
patients affected by Behçet’s disease (BD) recruited in our study.




Males, n (%) 17 (37) 8 (33)
Disease onset (mean ± SD) in years 32.16 ± 10.56 33.47 ± 11.17
Disease duration (mean ± SD) in months 144.5 ± 91.83 106.9 ± 88.49
Patients fulfilled the International Study 
Group Criteria in %
100 100
Patients fulfilled the International Criteria 
for BD in %
100 100
Clinical features (%)
Uveitis 13/46 (28) 8/24 (33)
Oral aphthosis 29/46 (63) 15/24 (62)
Genital aphthosis 7/46 (15) 4/24 (17)
Cutaneous disease 24/46 (52) 12/24 (50)
Gastrointestinal involvement 10/46 (22) 5/24 (21)
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inTrODUcTiOn
Behçet’s disease (BD) is a rare multisystemic inflammatory 
disorder clinically characterized by the “triple symptom com-
plex,” consisting of recurrent oral aphthosis, genital ulcers, and 
relapsing bilateral uveitis. Besides this classical clinical pattern, 
also other organ engagements including gastrointestinal tract, 
musculoskeletal, cardiovascular, and central nervous system, are 
documented (1–3). The recent understandings on cellular and 
molecular biology seem to suggest that an abnormal activation 
of both innate and adaptive immunity would be able to gener-
ate an inflammatory process leading to a CD4+ T lymphocytes 
clonal expansion which in turn produces high concentrations 
of both pro-inflammatory cytokines and cytotoxic CD8+ cells 
(4–11). The link between innate and adaptive immunity in 
patients with BD has been further clarified demonstrating that T 
cell immune response is skewed toward Th1 and Th17 polariza-
tion with decreased activity of regulatory T cells (12–14). The 
Th17 cells, play a critical role in the pathogenesis of a variety of 
autoimmune inflammatory diseases leading to production of 
Th17 effector cytokines, namely IL-17, IL-22, and IL-26 (15). 
This latter cytokine, belonging to the IL-10 family proteins, acts 
on monocytes to produce other pro-inflammatory mediators, 
such as IL-1β, IL-6, and tumor necrosis factor (TNF)-α which 
enhance the generation of new Th17 cells (16). Although the con-
tribution of IL-26 to the development of autoimmune diseases is 
undoubted, its role in BD pathogenesis is still unclear. Additional 
cytokines involved in mechanisms known to play a critical role 
in BD pathogenesis were recently associated to disease activity. 
Indeed, molecules such as Chitinase3-like1 regulating monocytes 
differentiation, as well as antibacterial and type 17 responses, was 
observed to be upregulated in BD patients compared to healthy 
control (HC). Interestingly, this cytokine was also seen to be 
associated to disease activity in BD, correlating positively with 
elevated IL-6 serum levels (17–19).
Tumor necrosis factor-α appears to be crucial in promot-
ing the development of the disease. This is documented by an 
overproduction of soluble TNF-α receptors and TNF-α sera levels 
spontaneously secreted by monocytes in active BD patients (20). 
Yet, elevated levels of TNF-α and soluble tumor necrosis factor 
receptors sTNFR1 and sTNFR2 have been found in BD patients. 
Moreover, increased systemic and synovial levels of sTNFRs 
in active BD strongly suggest a central role for the TNF/TNFR 
pathway in the pathogenesis of skin and joint involvement (21). 
Even though it is well documented that TNF blockade reduces the 
expression of different biological mediators and their receptors, 
the knowledge in BD regarding the role of the receptor gp130/
sIL-6Rb is still poor. This shared receptor is utilized by several 
related cytokines, including IL-6, IL-11, and IL-27, which in turn 
regulate cellular recruitment to local sites of inflammation, induce 
differentiation factor for Th17 cells, promote Th2 differentiation, 
and inhibit multiple T cell subsets (22).
Upregulation of TNF family members involved in T and 
B lymphocytes activation including APRIL/TNFSF13, BAFF/
TNFSF13B, sCD30/TNFRSF8 were also observed in BD patients 
underling a potential role of these cytokines in the immune 
response (23, 24).
Although literature data have proven that several cytokines are 
involved in BD pathogenesis, to date, biologic markers correlat-
ing with the disease activity have not yet been well recognized. 
Moreover, in the context of the same disease, it is difficult to 
identify a subset of disease signed by a specific cytokine pro-
file. Therefore, the purpose of this work was to investigate the 
potential role of specific circulating biomarkers of inflammation 
involved in adaptive and innate immune response in BD, in order 




Fifty-four serum samples were routinely collected and ana-
lyzed from 46 consecutive BD patients (17 males, 29 females, 
mean age 45.5 ±  11.3  years), who met the International Study 
Group Criteria (ISGC) (25) and the International Criteria for 
BD (ICBD) (26) and from 19 HC (10 males, 9 females, mean 
age 43 ±  8.3  years) who attending the outpatient clinic at the 
Rheumatology Unit of the University of Bari and who are nega-
tive for BD criteria (ISGC and ICBD). These subjects underwent 
detailed clinical and laboratory workup, in order to rule out any 
inflammatory, metabolic, and neoplastic disorders (in particular, 
they all showed inflammatory markers within normal values). 
All patients and controls were Caucasians of Italian origin. For 
seven patients, more than one serum sample was obtained during 
an active phase of disease, resulting in a total of 54 BD samples. 
Moreover, the samples were collected every 3 to 4 months and 
in case of disease relapse. Table 1 summarizes the clinical and 
demographic characteristics of BD patients. The primary aim of 
the study was to compare a cytokine profile between BD patients 
and HC; the secondary aim was to evaluate potential correlations 
between these putative circulating biomarkers, the status of 
disease activity, and the specific organ involvement at the time of 
sample collection. According to several other studies correlating 
circulating biomarkers with disease activity, BD patients were 
included in active BD group when they had at least two of the fol-
lowing clinical findings: uveitis, oral aphthosis, genital aphthosis, 
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cutaneous disease, and gastrointestinal involvement (6, 9, 27–29). 
More specifically, anterior and posterior uveitis were observed 
in 4/13 and 9/13 patients, whereas gastrointestinal involvement 
was endoscopically characterized by the presence of typical oval 
ulcers mostly localized in the terminal ileum. Written informed 
consent was obtained both from patients and HC. The study 
protocol was reviewed and approved by the Ethical Committee 
of the Medical University of Bari. Demographic and clinical 
information was obtained through structured interview, review 
of medical records, physical examination, and laboratory tests.
Multiplex Bead analysis
A panel of 25 serum cytokines [APRIL/TNFS13, BAFF/
TNFSF13B, sCD30/TNFRSF8, sCD163, Chitinase3-like1, gp130/
sIL-6Rb, IFNb, sIL-6Ra, IL-10, IL-11, IL-19, IL-20, IL-26, IL-27 
(p28), IL-28A/IFN-lambda2, IL-29/IFN-lambda1, IL-32, IL-34, 
IL-35, LIGHT/TNFSF-14, Pentraxin-3, sTNF-R1, sTNF-R2, 
TSLP, TWEAK/TNFSF-12] were simultaneously quantified using 
a Bio-Rad cytokine bead arrays according to the manufacturers’ 
instructions. Data analysis was performed using the Bioplex 
manager software 6.0.
statistical analysis
Statistical analyses were performed using GraphPad Prism 5 soft-
ware. Two-tailed Mann–Whitney test (for two non-parametric 
groups) and Student’s t-test (for two parametric groups) were 
used for statistical comparisons between groups. Significance in 
multiple comparisons was by one-way analysis of variance with 
a Bonferroni correction or Kruskall–Wallis test with a Dunn’s 
multiple comparison correction. Correlations were calculated 
using Spearman’s correlation (two-tailed p-value) as well as 
Pearson’s correlation test when required. Significance was defined 
as p < 0.05.
resUlTs
clinical characteristics of BD Patients
Overall, 54 serum samples were obtained from 46 BD patients, 
and 31 of these (57%) were collected from patients with active 
disease. The main demographic and clinical characteristics of the 
subjects involved in this study are shown in Table 1. Moreover, 
27 serum samples were obtained from HLA-B51-positive BD 
patients (50%) and at the time of serum collection patients 
were receiving the following treatments: TNF inhibitors 21/54, 
DMARDs combined with corticosteroids 14/54, DMARDs alone 
10/54, corticosteroids 3/54, anti-IL-1 agents 3/54, and three 
patients were no treated.
elevated cytokine levels of chitinase3-
like1, gp130/sil-6rb, il-11, il-26, 
sTnF-r1, and sTnF-r2 in BD Patients in 
comparison to healthy controls
Circulating levels of 25 cytokines were measured in serum samples 
obtained from BD patients (n = 54) and HC (n = 19). Cytokine 
levels of IL-10, IL-27 (p28), IL-28A/IFN-lambda2, IL-29/IFN-
lambda1, IL-32, IL-34, and LIGHT/TNFSF-14 were found in less 
than 50% of samples collected; for this reason these cytokines were 
not included in the analysis. No differences between BD patients 
and HC, in serum levels of APRIL/TNFS13, BAFF/TNFSF13B, 
sCD30/TNFRSF8, sCD163, IFNb, sIL-6Ra, IL-19, IL-20, IL-35, 
Pentraxin-3, TSLP, and TWEAK/TNFSF-12 were observed. In 
contrast, serum levels of Chitinase3-like1 (p = 0.009), gp130/sIL-
6Rb (p = 0.002), IL-11 (p = 0.008), IL-26 (p < 0.001), sTNF-R1 
(p < 0.001), and sTNF-R2 (p < 0.001) were significantly higher 
in BD than HC (Figure 1). Correlation study revealed significant 
correlation between cytokines showed to be upregulated in serum 
from BD patients. Among these, strong correlation was found 
between gp130/sIL-6Rb and sTNF-R1 (r =  0.706, p <  0.001), 
sTNF-R2 (r = 0.783, p < 0.001), sCD163 (r = 0.775, p < 0.001), 
TWEAK/TNFSF-12 (r  =  0.775, p  <  0.001), and sIL-6Ra 
(r = 0.705, p < 0.001) serum levels. sTNF-R1 also correlated with 
TSLP (r = 0.730, p < 0.001) and sTNF-R2 (r = 0.739, p < 0.001). 
Moreover, sTNF-R2 serum levels positively correlated with TSLP 
(r = 0.772, p < 0.001) and sCD163 (r = 0.724, p < 0.001) (Table 
S1 in Supplementary Material).
serum cytokine Profiles and Their 
correlation with Disease activity and 
clinical Features
As shown in Figure 2, BD patients were divided into two sub-
groups based on the disease activity. In active BD group were 
included patients characterized by at least two of the following 
clinical findings: uveitis, oral aphthosis, genital aphthosis, cutane-
ous disease, gastrointestinal involvement. Twenty-three serum 
samples were collected from inactive BD patients (8 males, 15 
females, mean age 44.6 ± 11.01 years) and 31 from active patients 
(12 males, 19 females, mean age 46.1  ±  11.67  years). Serum 
levels of sTNF-R1 and sTNF-R2 resulted higher in both active 
BD (p =  0.002 and p =  0.002, respectively) and inactive BD 
(p = 0.0101 and p = 0.002, respectively) subgroup than HC, while 
Chitinase3-like1 (p  =  0.042) and gp130/sIL-6Rb (p  =  0.008) 
serum levels were significantly higher in inactive BD as well as 
IL-26 (p = 0.002) in active BD than HC (Figure 2). Interestingly, 
among significantly serum cytokines upregulated in inactive BD 
and active BD patients, gp130/sIL-6Rb strongly correlated with 
sTNF-R2 (r = 0.716, p < 0.001), TWEAK/TNFSF-12 (r = 0.821, 
p < 0.001), IL-26 (r = 0.773, p = 0.007) serum levels, and sTNF-
R1 was to correlate with sTNF-R2 (r = 0.877, p < 0.001), IL-26 
(r = 0.773, p = 0.007), and IL-20 (r = 0.709, p = 0.0018) serum 
levels. In contrast, active BD subgroup revealed sTNF-R1 and 
TSLP (r = 0.769, p < 0.001) serum levels strong positively cor-
relation. Moreover, sTNF-R2 serum levels positively correlated 
with TSLP (r =  0.830, p <  0.001), gp130/sIL-6Rb (r =  0.818, 
p <  0.001), and sCD163 (r =  0.725, p <  0.001) (Table S2 in 
Supplementary Material). To determine the relationship between 
clinical features and the circulating levels of inflammatory mark-
ers, we measured and compared cytokine levels in serum from 
patients who presented at the time of blood collection mucocu-
taneous manifestations with (MO-BD) or without (M-BD) ocular 
involvement (Figure  3). Results showed significant enhanced 
levels of Chitinase3-like1 (p = 0.039) in M-BD but no differences 
were identified in MO-BD subgroup (p = 0.1035) compared with 
FigUre 1 | serum cytokine profile in patients with BD. BD patients (n = 54) showed upregulation of serum levels of Chitinase3-like1, gp130/sIL-6Rb, IL-11, 
IL-26, sTNF-R1, and sTNF-R2 compared with HC (n = 19). Mann–Whitney U-test and Student’s t-test were carried out to check for statistical significance between 
groups when required (***p < 0.001, **p < 0.01, *p < 0.05). The central line represents the distribution median, boxes span 25th to 75th percentiles, and error bars 
extend from 10th to 90th percentiles. Dots (°) are outlier values, higher than the 90th percentile. Abbreviations: HC, healthy controls; BD, Behçet’s disease.
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HC. Serum levels of sTNF-R1 and sTNF-R2 were higher in both 
M-BD (p =  0.0155 and p =  0.0066, respectively) and MO-BD 
(p <  0.001 and p <  0.001, respectively) than HC. In addition, 
elevated serum levels of gp130/sIL-6Rb (p  <  0.001), sIL-6Ra 
(p =  0.005), IL-11 (p =  0.027), IL-26 (p =  0.002), and TSLP 
(p =  0.0103) were also observed in MO-BD compared to HC. 
Interestingly, we observed that gp130/sIL-6Rb (p = 0.043), sIL-
6Ra (p = 0.029), IL-35 (p = 0.026), and TSLP (p = 0.013) serum 
levels were significantly enhanced in MO-BD compared to M-BD 
subgroup (Figure  3). Correlation analysis among all evaluated 
cytokines was also assessed. Notably, stronger significant correla-
tion was revealed in MO-BD compared with M-BD subgroup 
(Table S3 in Supplementary Material).
linear regression analysis between 
serum cytokine levels and Disease 
Duration
A linear regression analysis of cytokine serum levels in all patients 
as well as in disease activity and clinical features subgroups as 
a function of disease duration was assessed. No significant 
correlations were obtained in all patients and in active BD 
subgroup (Table S4 in Supplementary Material). In contrast, 
Chitinase3-like1 was found significant in inactive BD, M-BD, 
and MO-BD subgroup (rs = 0.277 p = 0.025, rs = 0.188 p = 0.011, 
rs =  0.274 p =  0.038, respectively) (Table S4 in Supplementary 
Material). Moreover, significant results were found in both M-BD 
and MO-BD subgroups for sCD163 (rs =  0.124 p =  0.041 and 
rs = 0.473 p = 0.003, respectively) and gp130/sIL-6Rb (rs = 0.162 
p = 0.018 and rs = 0.645 p < 0.001, respectively). In addition, sIL-
6Ra revealed significant correlation in M-BD (rs = 0.157 p = 0.02) 
while sTNF-R1 (rs  =  0.628 p  <  0.001), TWEAK/TNFSF-12 
(rs = 0.723 p < 0.001), and sCD30/TNFRSF8 (rs = 0.39 p = 0.010) 
were significantly correlated to disease duration in MO-BD sub-
group (Table S4 in Supplementary Material; Figure 4).
DiscUssiOn
Our study was aimed at investigating a core set of cytokines in a 
cohort of patients mainly affected by the most common clinical 
manifestations of BD, including mucosal, skin, and ocular involve-
ment, in order to assess any potential correlation between these 
circulating biomarkers, disease activity, and the specific clinical 
features of disease. First of all, we found elevated levels of several 
inflammatory markers in BD patients including Chitinase3-like1, 
gp130/sIL-6Rb, IL-11, IL-26, sTNF-R1, and sTNF-R2 compared 
with HC. Comparing HC with disease activity, we observed 
enhanced levels of sTNF-R1 and sTNF-R2 in both active BD 
and inactive BD subgroups, while Chitinase3-like1 and gp130/
FigUre 2 | serum cytokine profile analysis in BD patients with different disease activity. Serum cytokine levels in inactive BD (n = 23), active BD (n = 31) 
patients, and HC (n = 19). Analysis of variance was used for data comparison (***p < 0.001, **p < 0.01, *p < 0.05). The central line represents the distribution 
median, boxes span 25th to 75th percentiles, and error bars extend from 10th to 90th percentiles. Dots (°) are outlier values, higher than the 90th percentile. 
Abbreviations: BD, Behçet’s disease; HC, healthy controls.
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sIL-6Rb serum levels were significantly higher in inactive BD as 
well as IL-26 in active BD than HC. Furthermore, M-BD patients 
showed enhanced levels of Chitinase3-like1, sTNF-R1, and 
sTNF-R2 compared with HC as well as increased levels of gp130/
sIL-6Rb, sIL-6Ra, IL-11, IL-26, IL-35, sTNF-R1, sTNF-R2, and 
TSLP were found in MO-BD compared with HC. Interestingly, 
enhanced levels of gp130/sIL-6Rb, sIL-6Ra, IL-35, and sTNF-R1 
between MO- and M-BD were also found.
Chitinase3-like1, an inflammatory biomarker of endothelial 
dysfunction without chitinase activity, is secreted from activated 
neutrophils and macrophages in several pathological conditions 
characterized by tissue injury and inflammation (30). In this 
regard, it has been demonstrated that Chitinase3-like1 corre-
lates with the severity of skin lesions in patients with psoriatic 
arthritis but not in those with psoriasis vulgaris alone (31), being, 
however, its serum levels increased in psoriasis vulgaris and in 
generalized pustular psoriasis (32). Chitinase3-like1 has recently 
received considerable attention as marker for inflammation in BD 
patients (33, 34). Indeed a Korean study on 112 patients with BD 
whose main clinical features were recurrent oral ulcers and skin 
lesions, has shown increased serum levels of Chitinase3-like1 and 
a positive correlation with disease activity (17). These results are 
in agreement with Bilen et al. that showed higher serum levels of 
Chitinase3-like1 in BD patients compared with HC, albeit they 
did not correlate with disease activity (35). Similarly, we found 
enhanced levels of Chitinase3-like1 in M-BD group, even if its 
values were higher in the inactive BD group. Besides Chitinase3-
like1, for the first time we observed the upregulation of IL-11 
in our BD patients. This pleiotropic gp130-signaling cytokine, is 
able to induce anti-inflammatory and mucosal protective effects 
in a variety of animal models of acute and chronic inflammation, 
such as mucositis and inflammatory bowel diseases. In particular, 
IL-11 may exert anti-inflammatory effects by reducing cytokines 
production by macrophages (36). In vitro studies suggest that 
recombinant human IL-11 inhibits TNF-α, IL-1β, IL-12, IL-6, 
and nitric oxide production from activated macrophages reduc-
ing inflammation and tissue damage and promoting mucosal 
repair (37). Data from our study suggest that IL-11 does not cor-
relate with disease activity and there are no significant differences 
between the active and inactive BD groups. Interestingly, we also 
found a higher level of IL-11 in the MO-BD group rather than in 
M-BD alone, even though it has been suggested that this cytokine 
is connected to repair processes of mucosal tissue damage (37).
Regarding gp130/sIL-6Rb, inactive BD showed higher values 
of this cytokine than HC. Gp130 also known as beta-subunit of 
the IL-6 receptor (sIL-6Rb) or CD130 is a ubiquitously expressed 
signal-transducing receptor that forms part of the receptor 
complex for several cytokines, including IL-6, IL-11, and IL-27 
FigUre 3 | serum cytokine profile in mucocutaneous patients with (MO-BD) or without (M-BD) ocular involvement. Serum cytokine levels in M-BD 
(n = 35), MO-BD (n = 17) patients, and HC (n = 19). Analysis of variance was used for data comparison (***p < 0.001, **p < 0.01, *p < 0.05). The central line 
represents the distribution median, boxes span 25th to 75th percentiles, and error bars extend from 10th to 90th percentiles. Dots (°) are outlier values, higher than 
the 90th percentile. Abbreviations: HC, healthy controls; BD, Behçet’s disease; M-BD, mucocutaneous patients without ocular involvement; MO-BD, 
mucocutaneous patients with ocular involvement.
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FigUre 4 | linear regression analysis of serum cytokine levels versus disease duration. A positive strong correlation was found between gp130/sIL-6Rb, 
sTNF-R1, and TWEAK/TNFSF-12 circulating levels and disease duration in MO-BD (mucocutaneous patients with ocular involvement) subgroup.
7
Lopalco et al. Biomarkers in Behçet’s Disease
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 200
(38). Classically, IL-6 activates gp130 by binding a non-signaling 
cognate IL-6 receptor, which then leads to the initiation of JAK/
STAT signaling, a pathway that is often constitutively switched on 
in several inflammatory processes (39). However, IL-6 responses 
can also be elicited through IL-6 trans-signaling mediated via 
a naturally occurring soluble IL-6R (40). Several biological 
processes, including the switch from neutrophil to mononuclear 
cell recruitment during inflammation, the leukocyte trafficking, 
activation, and apoptosis (41, 42), are due to IL-6 trans-signaling 
which is inhibited by a soluble form of gp130, in turn able to 
effectively bind the IL-6/sIL-6R complex and to prevent activa-
tion of membrane-bound gp130, modulating the severity of 
inflammatory responses (43, 44). The ability of soluble gp130 to 
downregulate the severity of inflammation and joint destruction 
in murine antigen induced arthritis has been demonstrated by a 
significant reduction in inflammatory infiltrate within the affected 
joints (45). Convincing proofs regarding the inflammatory role of 
the IL-6/sIL-6R complex derive also from the study of Curnow 
et  al. aimed at proving an insufficient lymphocytes apoptosis 
in uveitis able to induce an inflammatory process through the 
trans-signaling pathway (46). In this regard, in our study, we 
found enhanced levels of gp130/sIL-6Rb, especially in MO-BD 
group than M-BD, although no correlation with disease activity 
was observed. Finally, a strong correlation between gp130/sIL-
6Rb circulating levels and disease duration in MO-BD subgroup 
was also observed.
To the best of our knowledge, no studies have focused on the 
role of IL-26 in BD. In our study, serum concentration of IL-26 
was significantly higher in BD, especially in active BD, than in 
HC. IL-26, a member of the IL-10 cytokine family, capable of 
inducing the production of several pro-inflammatory cytokines, 
such as IL-1β, IL-8 and TNF-α (16), is released in large amount 
in response to classic pro-inflammatory stimuli and enhances 
chemotaxis of neutrophils (47). Interestingly, this cytokine may 
impair the responsiveness to itself in certain structural cells 
such as colon epithelial cell line suggesting its pathogenic role 
in inflammatory bowel diseases. Indeed, increased infiltration 
of IL-26-positive Th17 cells was found in the colon of Crohn’s 
disease patients (48) and elevated expression of IL-26 mRNA was 
observed in the colon of pediatric-onset ulcerative colitis (49) 
as well as in tonsils and Payer’s patches in response to microbial 
stimuli, thus suggesting a pivotal role in mucosal immunity for this 
cytokine (50). Moreover, in some dermatological diseases, such as 
psoriasis, IL-26 has been found more highly expressed in lesions 
than in normal skin, proving an important function in regulating 
the innate immunity of epithelial cells (51). Despite this cytokine 
would seem more related to a mucocutaneous disease subset, in 
our experiment, IL-26 serum levels were found higher in MO-BD 
group than M-BD alone, consequently its increased values are not 
discriminating for the mucocutaneous involvement.
A reasonable explanation of this discrepancy may lie in the 
fact that IL-26 expression should be directly sought in the skin 
lesions rather than in the serum from BD patients since the major 
source of IL-26 is provided by infiltration of Th17 lymphocytes in 
inflamed tissue (52).
Tumor necrosis factor-α is the main cytokine involved in acute 
inflammatory responses and stimulates the release of other pro-
inflammatory mediators. Endogenous mechanisms mediated 
through two distinct TNF receptor types 1 and 2 which are shed 
from cell surface as soluble forms (sTNF-R1 and sTNF-R2) may 
limit the systemic inflammation (53). As previously reported, 
increased serum concentrations of the soluble forms of mem-
brane receptor for TNF-α, sTNF-R1, and sTNF-R2, have been 
found in active BD (54) and demonstrated in several rheumatic 
diseases (55–58), however, controversial are data regarding their 
putative role as markers of disease activity. In particular, Turan 
et al. reported that increased sTNF-R2 may serve as a marker of 
disease activity in BD, especially in those patients with arthritis, 
furthermore an increased TNF-R2 expression was found in 
mucosal and cutaneous ulcers where mast cells were identified 
as the major source for this receptor (21). On the contray, in line 
with our study, Düzgün et al. found significantly increased serum 
levels of sTNF-R1 in BD patients compared with HC, even though 
they did not reflect active disease (20). Interestingly, higher levels 
of sTNF-R were observed in our cohort of BD patients than in 
HC; however, no differences were observed between the patients 
with mucocutaneous plus ocular involvement and those with 
the sole mucocutaneous symptoms. More recently, Ke et al. have 
proven that sTNF-R1 released by skin-derived mesenchymal 
stem cells is critical for inhibiting the differentiation of Th17 
cells, which are the major contributor of experimental murine 
models of autoimmune disease leading to IL-17A, IL-17F, IL-21, 
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and IL-22 production (59). Similarly to what was observed for 
serum levels of gp130/sIL-6Rb, important results were obtained 
analyzing the values of sTNF-R1 and sTNF-R2 versus disease 
duration: in particular a positive strong correlation was found 
between sTNF-R1 circulating levels and disease duration in 
MO-BD subgroup, thus suggesting as previously reported that 
BD appears to have a less aggressive clinical course over time 
related to disease duration (60).
The main limitations of our study are represented by the 
sample size that did not allow us to ascertain the actual correla-
tion of specific cytokines with the different subsets of disease as 
well as the absence of a disease control group. Moreover, at the 
time of samples collection, all of the patients were already taking 
immunosuppressive agents, which might have affected cytokine 
serum levels. Finally, we believe that not evaluating disease activ-
ity with outcome measures, due to the incompleteness of data, 
could represent another limitation of our study.
In conclusion, our findings were in agreement with several 
studies that showed that the immune response in BD is skewed 
toward a Th1 as well as Th17 pathway (61). Moreover, we 
observed the upregulation of chitinase3-like1 and IL-11 in BD. 
These molecules are produced by innate immune cells and lead to 
monocytes dendritic cell maturation and inhibition of TNF-α and 
IL-6 signaling (62, 63). Finally, this IL-6, TNF and Th17 signature 
could discriminate mucocutaneous patients with ocular involve-
ment from mucocutaneous patients without ocular involvement, 
even if further studies in a larger cohort of patients as well as a 
comparison with disease group are necessary. Our preliminary 
data could contribute to improve the knowledge regarding the 
role of specific target for novel therapies or for a different and 
more suitable use of biologic drug currently available, suggesting 
a possible role of these cytokines in the induction of specific BD 
clinical manifestations.
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